research use only

Taurochenodeoxycholic acid Caspase activator

Name: Taurochenodeoxycholic acid
Brand: Selleck Chemicals
SKU: S3865
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S3865

Taurochenodeoxycholic acid (Taurochenodeoxycholate, TCDCA, Chenodeoxycholyltaurine), a bile acid formed in the liver of most species, is used as a cholagogue and choleretic.

Chemical Structure

Molecular Weight: 499.70

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	Apoptosis related Ras STAT TNF-alpha Bcl-2 PD-1/PD-L1 Ferroptosis p53 RIP kinase c-RET MDM2/MDMX Myc IAP OXPHOS PERK Thymidylate Synthase FKBP ABC Transporter Heme Oxygenase PFKFB PKD Survivin Pyroptosis ASK Bcl-6 Nur77 DAPK TRADD TACE Cuproptosis
Related Products	Z-VAD-FMK Belnacasan (VX-765) Z-DEVD-FMK Q-VD-Oph Z-IETD-FMK Emricasan (IDN-6556) Ac-DEVD-CHO Z-LEHD-FMK TFA Z-VAD(OH)-FMK PAC-1 Z-YVAD-FMK Apoptosis Activator 2 Tasisulam Phenoxodiol (Haginin E) pro Caspase3 Antibody [H9J6] Caspase1 Antibody [D17C3] Cleaved Caspase3 (Asp175) Antibody [P20N20] NVP 231 Mentha Arvensis Leaf Extract Cordyceps Militaris Extract Cleaved Caspase7 (Asp198) Antibody [K17H18] Caspase2 Antibody [N15G7] Z-VAD Caspase-3 p12 Antibody [N15D21] Eleutherine Plicata Extract Lysinotus pauciflorus Extract (±)-Methyl Jasmonate Cleaved Caspase-3 Antibody [G2J3] Caspase-7 Antibody [H18L1] Alisol B Acetate

Chemical Information, Storage & Stability

Molecular Weight	499.70	Formula	C₂₆H₄₅NO₆S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	516-35-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Taurochenodeoxycholate, TCDCA, 12-Deoxycholyltaurine, Chenodeoxycholyltaurine, Chenyltaurine			Smiles	CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (200.12 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (10.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (2.50mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Taurochenodeoxycholic acid (TUDCA) induces dissociation of CD34+ HSCs from stromal cells by decreasing adhesion molecule expression. It induces bone marrow stem cell mobilization and differentiation into endothelial progenitor cells (EPCs) and enhances EPC proliferation, invasion, and tube formation via Akt and ERK activation^[1]. TCDCA induces the apoptosis process through the activation of caspase cascade in macrophages, and this process may be involved in PKC/JNK signaling pathway^[2].
In vivo	TUDCA has neuroprotective effects in neuronal cultures and positive effects on ischemia reperfusion in animal models, reducing infarct area and inflammation via attenuation of endoplasmic reticulum (ER) stress. TUDCA is incorporated into target cells via organic anion transporter (OATP) 2, OATP8, and the Na+‐taurocholate cotransporting polypeptide (NTCP). TUDCA inhibits neointimal hyperplasia by promoting apoptosis of smooth muscle cells via induction of MAP kinase phosphatase‐1 (MKP‐1) expression. In addition, TUDCA protects the hepatocytes and restores glucose homeostasis by reducing ER stress. TUDCA enhances neovascularization in vivo^[1]. TCDCA in dosages of 0.05 and 0.1g/kg can extremely significantly decrease the pulmonary coefficient in the model mice. TCDCA in a dosage of 0.2g/kg significantly decreases the pulmonary coefficient in the model mice (P<0.05); TCDCA in dosages of 0.05 and 0.1g/kg significantly reduce the pathological damages on their lungs; TCDCA can extremely significantly decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice (P>0.01), the expression level of MMP-9 extremely significantly increased (P>0.01), while it has no significant effects on MMP2. Thus, TCDCA has antagonistic actions on pulmonary fibrosis in mice^[3].
References	[1] https://pubmed.ncbi.nlm.nih.gov/25407160/ [2] https://pubmed.ncbi.nlm.nih.gov/27268718/ [3] https://pubmed.ncbi.nlm.nih.gov/23811455/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):